Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 19/20 | 0.90 |
| ▸ | CHUK | O15111 | 13/20 | 0.90 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.59 |
| ▸ | FLT4 | P35916 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | EPHB1 | P54762 | 1/20 | 0.59 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | BTK | Q06187 | 1/20 | 0.58 |
| ▸ | ITK | Q08881 | 1/20 | 0.58 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetamide SCHEMBL3550862 | 0.98 | IKBKB (0.86) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2768248 | 0.95 | IKBKB (1.00) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL2768217 | 0.93 | IKBKB (0.87) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2766541 | 0.91 | IKBKB (1.00) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2766177 | 0.91 | IKBKB (0.86) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2768682 | 0.91 | IKBKB (0.85) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL3039640 | 0.90 | IKBKB (0.79) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2765746 | 0.90 | IKBKB (0.84) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2768097 | 0.90 | IKBKB (0.88) | IKBKBCHUKRETCYP2C9EPHA1 | |
| SCHEMBL2768244 | 0.90 | IKBKB (0.86) | IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268855-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| EP-2001887-B1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-09-15 | — | — | EP | disclosed |
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | BALLELL-PAGES LLUIS | 2010-07-22 | — | — | US | disclosed |
| US-7737279-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-15 | — | — | US | disclosed |
| US-7732460-B2 | Heterocyclic compounds, their preparation and their use as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-7709483-B2 | Pyrrolo-quinoxalinone derivatives as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| EP-1963324-B1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-04-21 | — | — | EP | disclosed |
| EP-1954697-B1 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-02-24 | — | — | EP | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| US-20080280892-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-20080221110-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| US-20070185153-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | IL1R1, IDO1, TLR1 | IKBKB 419/4885CHUK 1939/4885RET 803/4885 |
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | NQO2, PPOX, ASNS | IKBKB 2650/4885CHUK 2168/4885RET 2937/4885 |
| US-20070185153-A1 | COMPOUNDS | NRDC, NISCH, MRPL21 | IKBKB 1580/4885CHUK 1187/4885RET 3341/4885 |
| US-20080221110-A1 | Compounds | NRDC, NISCH, MRPL21 | IKBKB 1580/4885CHUK 1187/4885RET 3341/4885 |
| US-20060270654-A1 | 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | IL1R1, IDO1, TLR1 | IKBKB 419/4885CHUK 1939/4885RET 803/4885 |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | IKBKB 556/4885CHUK 409/4885RET 4287/4885 |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | SDHA, SDHB, NNT | IKBKB 457/4885CHUK 378/4885RET 3457/4885 |
| US-20080280892-A1 | Compounds | NRDC, NACA, NAA50 | IKBKB 1644/4885CHUK 1154/4885RET 2839/4885 |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | MRPL21, NACA, NISCH | IKBKB 1541/4885CHUK 1120/4885RET 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.